Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Conjugated Estrogens Cream Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor

NCT01778985
View directory record Official record
Conditions
Pelvic Organ Prolapse, Menopause
Interventions
Premarin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

NCT00361569
View directory record Official record
Conditions
Menopause
Interventions
DR-2041a, DR-2041b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Not applicable Interventional Results available

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

NCT02524769
View directory record Official record
Conditions
Overactive Bladder
Interventions
conjugated estrogen
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 1 Interventional

Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis

NCT00167921
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Premarin® Vaginal Cream, Premarin® oral tablets
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2007 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 3 Interventional

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

NCT00803335
View directory record Official record
Conditions
Pelvic Organ Prolapse, Vaginal Atrophy
Interventions
Vaginal conjugated estrogen cream 0.5gm, Vaginal conjugated estrogen cream 1.0gm
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 3 Interventional

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

NCT00137371
View directory record Official record
Conditions
Atrophic Vaginitis, Atrophy, Vaginitis
Interventions
PVC (daily for 21 days, 7 days off), PVC (twice weekly)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
480 participants
Timeline
2005 – 2007
U.S. locations
32
States / cities
Tucson, Arizona • Encinitas, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2007 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal and Urinary Microbiome Trial

NCT02869165
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections
Interventions
Conjugated equine estrogen topical cream, Apricot kernel oil
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 8, 2026, 11:04 PM EDT
Terminated Phase 4 Interventional Results available

Postmenopausal Pessary Users: Estrogen Versus Trimosan

NCT03943823
View directory record Official record
Conditions
Vaginosis, Vaginosis, Bacterial, Vaginal Discharge
Interventions
Estrogen vaginal cream, Trimo-San vaginal gel
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 8, 2026, 11:04 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Investigation of the Effect of the Female Urinary Microbiome on Incontinence

NCT02835846
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Nocturia
Interventions
Estrogen Cream
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Not applicable Interventional Results available

Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy

NCT02691936
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause
Interventions
CO2 fractionated vaginal laser, Estrogens, Conjugated (USP)
Device · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Stanford, California • Washington D.C., District of Columbia • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 8, 2026, 11:04 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery

NCT02860897
View directory record Official record
Conditions
Estrogen, Menopause, Pelvic Floor Disorders, Surgery
Interventions
Premarin, Vagifem
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 90 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Not applicable Interventional Results available

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

NCT04301934
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Mona Lisa Touch, Conjugated estrogen, Estradiol
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 8, 2026, 11:04 PM EDT
Terminated Phase 4 Interventional Results available

Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

NCT03018106
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Ospemifene, Vaginal conjugated estrogens
Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen

NCT02431897
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions
Conjugated Estrogens Cream, Placebo Cream
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
48 Years and older · Female only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 8, 2026, 11:04 PM EDT
Terminated Not applicable Interventional Results available

Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse

NCT01648751
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Vaginal estrogen, Placebo
Drug
Lead sponsor
Pamela Moalli
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 11:04 PM EDT
Completed Phase 4 Interventional Results available

Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy

NCT03996603
View directory record Official record
Conditions
Female Urogenital Diseases, Vaginal Atrophy, Postmenopausal Atrophic Vaginitis, Genitourinary Disease, Postmenopausal Symptoms
Interventions
Conjugated Estrogens Cream
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 8, 2026, 11:04 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

NCT02213757
View directory record Official record
Conditions
Microscopic Hematuria
Interventions
Premarin vaginal estrogen cream, Placebo vaginal cream
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 8, 2026, 11:04 PM EDT